Cost-Effectiveness of Circulating Tumor DNA–Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial
ctDNA-guided atezolizumab adjuvant therapy proves to be a cost-effective strategy for MIBC, optimizing health care resource allocation and reducing overtreatment while improving patient outcomes. More standardized ctDNA testing protocols and transparent reporting of ctDNA status distributions are essential.
Authors
- Zihan Xue (ORCID: https://orcid.org/0009-0002-6750-0934)
- Zhouliang Wu
- Yunkai Qie (ORCID: https://orcid.org/0000-0001-7848-3653)
- Houyuan Chen (ORCID: https://orcid.org/0009-0009-8191-7550)
- Yuda Lin (ORCID: https://orcid.org/0009-0003-0430-1302)
- Chong Shen (ORCID: https://orcid.org/0009-0005-1580-1577)
- Shan Liang
- Rongjiang Li
- Hailong Hu
- Peng Li
Institutions
- Second Hospital of Tianjin Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1200/op-25-01242
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00